Histrelin

Bezeichnung:Histrelin

CAS-Nr76712-82-8

Englisch Name:Histrelin

CBNumberCB8480046

SummenformelC66H86N18O12

Molgewicht1323.53

MOL-Datei76712-82-8.mol

Histrelin physikalisch-chemischer Eigenschaften

alpha	D20 -33.9° (c = 1 in acetic acid)
Dichte	1.46±0.1 g/cm3(Predicted)
storage temp.	-20°C
Löslichkeit	Aqueous Acid (Slightly), DMSO (Slightly), Methanol (Slightly)
Aggregatzustand	powder
pka	9.82±0.15(Predicted)
Stabilität	Hygroscopic

Sicherheit

Kennzeichnung gefährlicher	T
R-Sätze:	60
S-Sätze:	53-22-36/37/39-45
WGK Germany	3
RTECS-Nr.	OK6370800
HS Code	3504009000
Giftige Stoffe Daten	76712-82-8(Hazardous Substances Data)

Gefahreninformationscode (GHS)

Histrelin Chemische Eigenschaften,Einsatz,Produktion Methoden

R-Sätze Betriebsanweisung:
R60:Kann die Fortpflanzungsfähigkeit beeinträchtigen.
S-Sätze Betriebsanweisung:
S53:Exposition vermeiden - vor Gebrauch besondere Anweisungen einholen.
S22:Staub nicht einatmen.
S36/37/39:Bei der Arbeit geeignete Schutzkleidung,Schutzhandschuhe und Schutzbrille/Gesichtsschutz tragen.
S45:Bei Unfall oder Unwohlsein sofort Arzt zuziehen (wenn möglich, dieses Etikett vorzeigen).
Beschreibung
Histrelin, a synthetic gonadotrophin-releasing hormone (GnRH) agonist, was introduced as a first-line therapy for the treatment of central precocious puberty. When administered over a prolonged period, it suppresses the release of gonadotrophin, inhibits ovarian and testicular steroidogenesis, and prevents sexual maturation. Superior to the traditional therapy with progestational agents, histrelin appears to have decelerating effects on skeletal maturation allowing more statural growth and significantly increased final adult height. Histrelin has also been used to treat other disorders including endometriosis, polycystic ovarian disease, uterine leiomyomas, severe premenstrual syndrome and to prevent acute intermittent porphyria.
Originator
Johnson & Johnson (U.S.A.)
Verwenden
[des-Gly¹⁰, D-His(Bzl)⁶]-LH-RH ethylamide has been used:
- for inducing Batrachoseps gravid females to oviposit
- for comparing the effect of LHRH (luteinizing hormone-releasing hormone) agonists and dopamine antagonists in Lithobates pipiens
- for inducing oviposition in females of Taricha granulosa and Ensatina eschscoltzii
- to induce spawning in Spea hammondii adults
Verwenden
LHRH agonist.
Definition
ChEBI: An oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, 1-benzyl-D-histidyl, leucyl, arginyl, and N-ethylprolinamide residues joined in sequence. It is a synthetic nonapeptide analogue of gonadotro in-releasing hormone, and is used as a subcutaneous hydrogel implant (particularly as the diacetate salt) for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty.
Trademarks
Supprelin (Roberts Pharmaceutical).
Biochem/physiol Actions
Glp-His-Trp-Ser-Tyr-His(Bzl)-Leu-Arg-Pro-NHEt ([des-Gly10, D-His(Bzl)6]-LH-RH) is a GnRH (gonadotropin-releasing hormone) agonist, histerelin. GnRH (Glp-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2), which is also referred as LHRH (luteinizing hormone-releasing hormone) or gonadorelin, is crucial for mammalian reproduction and is released from hypothalamic neurons. It is responsible for the secretion of gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), from the pituitary glands. Mutations in GnRH are associated with normosmic congenital hypogonadotropic hypogonadism. Histerelin is used for the treatment of central precocious puberty in children. It inhibits actions of sex steroids on the male and female reproductive organs.

Histrelin Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

76712-82-8, Histrelin Verwandte Suche:

Send Inquriy